Cruz-Monserrate Zobeida, Vervoort Hélène C, Bai Ruoli, Newman David J, Howell Stephen B, Los Gerrit, Mullaney Jeffrey T, Williams Michael D, Pettit George R, Fenical William, Hamel Ernest
Building 469, Room 104, National Cancer Institute at Frederick, Frederick, MD 21702, USA.
Mol Pharmacol. 2003 Jun;63(6):1273-80. doi: 10.1124/mol.63.6.1273.
The marine ascidian Diazona angulata was the source organism for the complex cytotoxic peptide diazonamide A. The molecular structure of this peptide was recently revised after synthesis of a biologically active analog of diazonamide A in which a single nitrogen atom was replaced by an oxygen atom. Diazonamide A causes cells to arrest in mitosis, and, after exposure to the drug, treated cells lose both interphase and spindle microtubules. Both diazonamide A and the oxygen analog are potent inhibitors of microtubule assembly, equivalent in activity to dolastatin 10 and therefore far more potent than dolastatin 15. This inhibition of microtubule assembly is accompanied by potent inhibition of tubulin-dependent GTP hydrolysis, also comparable with the effects observed with dolastatin 10. However, the remaining biochemical properties of diazonamide A and its analog differ markedly from those of dolastatin 10 and closely resemble the properties of dolastatin 15. Neither diazonamide A nor the analog inhibited the binding of [3H]vinblastine, [3H]dolastatin 10, or [8-14C]GTP to tubulin. Nor were they able to stabilize the colchicine binding activity of tubulin. These observations indicate either that diazonamide A and the analog have a unique binding site on tubulin differing from the vinca alkaloid and dolastatin 10 binding sites, or that diazonamide A and the analog bind weakly to unpolymerized tubulin but strongly to microtubule ends. If the latter is correct, diazonamide A and its oxygen analog should have uniquely potent inhibitory effects on the dynamic properties of microtubules.
海洋被囊动物棱角重盘海鞘是复杂细胞毒性肽重盘酰胺A的来源生物。该肽的分子结构最近在合成重盘酰胺A的一种生物活性类似物后得到修正,在这种类似物中一个氮原子被一个氧原子取代。重盘酰胺A使细胞停滞于有丝分裂期,并且在接触该药物后,处理过的细胞失去间期和纺锤体微管。重盘酰胺A及其氧类似物都是微管组装的强效抑制剂,活性与多拉司他汀10相当,因此远比多拉司他汀15强效。这种对微管组装的抑制伴随着对微管蛋白依赖性GTP水解的强效抑制,这也与多拉司他汀10所观察到的效应相当。然而,重盘酰胺A及其类似物的其余生化特性与多拉司他汀10明显不同,且与多拉司他汀15的特性非常相似。重盘酰胺A及其类似物都不抑制[3H]长春碱、[3H]多拉司他汀10或[8-14C]GTP与微管蛋白的结合。它们也不能稳定微管蛋白的秋水仙碱结合活性。这些观察结果表明,要么重盘酰胺A及其类似物在微管蛋白上有一个不同于长春花生物碱和多拉司他汀10结合位点的独特结合位点,要么重盘酰胺A及其类似物与未聚合的微管蛋白弱结合,但与微管末端强结合。如果后者正确,重盘酰胺A及其氧类似物应该对微管的动态特性有独特的强效抑制作用。
Jpn J Cancer Res. 2000-7
Arch Biochem Biophys. 2019-12-9
Curr Org Synth. 2025
Naunyn Schmiedebergs Arch Pharmacol. 2025-2-24
Mol Biotechnol. 2024-9-26
Comb Chem High Throughput Screen. 2024
Arch Biochem Biophys. 2022-9-30
Arch Biochem Biophys. 2019-12-9